Meeting
2020 ASCO Virtual Scientific Program
Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease.
Authors
Andrea De Censi
Division of Medical Oncology, E.O. Galliera Hospital, Genoa, Italy
Andrea De Censi , Harriet Ann Johansson , Thomas Helland , Matteo Puntoni , Tania Buttiron Webber , Debora Macis , Valentina Aristarco , Irene Maria Briata , Davide Serrano , Mauro D'Amico , Ersilia Bifulco , Steinar Hustad , Håvard Søiland , Bernardo Bonanni , Gunnar Mellgren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Cancer Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Clinical Trial Registration Number
NCT01357772
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1553)
DOI
10.1200/JCO.2020.38.15_suppl.1553
Abstract #
1553
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Randomized, placebo controlled, phase III trial of low-dose tamoxifen in women with intraepithelial neoplasia.
First Author: Matteo Puntoni
Poster
2018 ASCO Annual Meeting
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
First Author: Toshimi Takano
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan